Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained a 'Perform' rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $23 to $25.
July 28, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained a 'Perform' rating on ACADIA Pharmaceuticals and raised the price target from $23 to $25.
The news of Oppenheimer maintaining a 'Perform' rating and raising the price target for ACADIA Pharmaceuticals is directly related to the company and is likely to have a positive impact on its stock price in the short term. Investors may see this as a sign of confidence in the company's performance and future prospects, which could drive buying activity and push the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100